Metformin Zentiva (Metformin Hydrochloride)

Metformin Hydrochloride inhibits mitochondrial complex I, which reduces hepatic gluconeogenesis. It also activates AMP‑activated protein kinase (AMPK), enhancing peripheral glucose uptake and improving insulin sensitivity, thereby lowering overall blood glucose concentrations.

The appropriate dose of Metformin Zentiva is individualized by the prescribing clinician based on the patient’s renal function, glycemic targets, and tolerability. Dosage adjustments are made during treatment to achieve optimal glucose control while minimizing side effects.

Metformin Zentiva falls under an unknown pregnancy category. It should only be used during pregnancy if the potential benefits outweigh the risks, and it is generally avoided unless specifically indicated. Breastfeeding mothers should consult their healthcare provider, as metformin does pass into breast milk.

To place an order, submit an enquiry on the Metformin Zentiva product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Metformin Zentiva belongs to the biguanide class, which is often first‑line therapy for type 2 diabetes because of its efficacy, low risk of hypoglycemia and weight neutrality. Compared with sulfonylureas, it does not stimulate insulin release, and unlike insulin, it is administered orally and does not cause weight gain.

Metformin Zentiva should be stored at ambient temperature, below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Metformin Zentiva is taken orally, usually with meals to reduce gastrointestinal discomfort. Tablets are swallowed whole with a full glass of water. The exact timing and frequency are determined by the prescribing clinician.

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal or hepatic impairment, excessive alcohol intake, or hypoxia. Other serious concerns include severe skin reactions, hepatic dysfunction, and vitamin B12 deficiency with long‑term use.

Metformin Zentiva is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, known hypersensitivity to metformin, and those receiving iodinated contrast studies without adequate renal monitoring.